These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22101966)

  • 1. Preparation and in vitro/in vivo evaluation of microparticle formulations containing meloxicam.
    Eroglu H; Burul-Bozkurt N; Uma S; Oner L
    AAPS PharmSciTech; 2012 Mar; 13(1):46-52. PubMed ID: 22101966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects.
    Gschwend MH; Erenmemişoğlu A; Martin W; Tamur U; Kanzik I; Hincal AA
    Arzneimittelforschung; 2007; 57(5):264-8. PubMed ID: 17598697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanostructured lipid carriers based nanogel for meloxicam delivery: mechanistic, in-vivo and stability evaluation.
    Khurana S; Jain NK; Bedi PM
    Drug Dev Ind Pharm; 2015; 41(8):1368-75. PubMed ID: 25151872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer.
    Patel MM; Amin AF
    Drug Deliv; 2011 May; 18(4):281-93. PubMed ID: 21138335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meloxicam carbopol-based gels: characterization and evaluation.
    Sareen R; Kumar S; Gupta GD
    Curr Drug Deliv; 2011 Jul; 8(4):407-15. PubMed ID: 21453256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.
    Ghorab MM; Abdel-Salam HM; El-Sayad MA; Mekhel MM
    AAPS PharmSciTech; 2004 Jul; 5(4):e59. PubMed ID: 15760056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation optimization of meloxicam sodium gel using response surface methodology.
    Chang JS; Huang YB; Hou SS; Wang RJ; Wu PC; Tsai YH
    Int J Pharm; 2007 Jun; 338(1-2):48-54. PubMed ID: 17360134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.
    Bachhav YG; Patravale VB
    Acta Pharm; 2010 Jun; 60(2):153-63. PubMed ID: 21134852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
    Alladi S; Shastri NR
    Arch Pharm Res; 2015; 38(5):801-12. PubMed ID: 24752862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ion-pair formation combined with a penetration enhancer as a dual strategy to improve the transdermal delivery of meloxicam.
    Jiang Q; Wang J; Ma P; Liu C; Sun M; Sun Y; He Z
    Drug Deliv Transl Res; 2018 Feb; 8(1):64-72. PubMed ID: 29181834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meloxicam β-cyclodextrin transdermal gel: physicochemical characterization and in vitro dissolution and diffusion studies.
    Rasool BK; Gareeb RH; Fahmy SA; Rasool AA
    Curr Drug Deliv; 2011 Jul; 8(4):381-91. PubMed ID: 21453259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan Encapsulated Meloxicam Nanoparticles for Sustained Drug Delivery Applications: Preparation, Characterization, and Pharmacokinetics in Wistar Rats.
    Yegireddy M; Nadoor P; Rao S; Hanumanthu PB; Rajashekaraiah R; Ramachandrappa SC; Halemani GM; Mannem S; Prasad TNVKV; Ubaradka S
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and development of di-dependent microparticulate system for colon-specific drug delivery.
    Patel MM
    Drug Deliv Transl Res; 2017 Apr; 7(2):312-324. PubMed ID: 28138901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel combination of Soluplus
    Taha NF; Emam MF; Emara LH
    Drug Dev Ind Pharm; 2020 Aug; 46(8):1362-1372. PubMed ID: 32615818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of solubility enhancement on nasal absorption of meloxicam.
    Horváth T; Ambrus R; Völgyi G; Budai-Szűcs M; Márki Á; Sipos P; Bartos C; Seres AB; Sztojkov-Ivanov A; Takács-Novák K; Csányi E; Gáspár R; Szabó-Révész P
    Eur J Pharm Sci; 2016 Dec; 95():96-102. PubMed ID: 27260088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
    Şengel-Türk CT; Hasçiçek C; Dogan AL; Esendagli G; Guc D; Gönül N
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1107-16. PubMed ID: 22348284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and characteristics of gellan gum beads for modified release of meloxicam.
    Osmałek T; Milanowski B; Froelich A; Szybowicz M; Białowąs W; Kapela M; Gadziński P; Ancukiewicz K
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1314-1329. PubMed ID: 28420283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of meloxicam in situ implant formulation by quality by design principle.
    Ibrahim HM; Ahmed TA; Hussain MD; Rahman Z; Samy AM; Kaseem AA; Nutan MT
    Drug Dev Ind Pharm; 2014 Jan; 40(1):66-73. PubMed ID: 23298324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low density multiparticulate system for pulsatile release of meloxicam.
    Sharma S; Pawar A
    Int J Pharm; 2006 Apr; 313(1-2):150-8. PubMed ID: 16540268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.
    Vivancos M; Barker J; Engbers S; Fischer C; Frederick J; Friedt H; Rybicka JM; Stastny T; Banse H; Cribb AE
    Can Vet J; 2015 Jul; 56(7):730-6. PubMed ID: 26130835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.